Biorestorative Therapies (BRTX)
(Real Time Quote from BATS)
$1.37 USD
0.00 (0.00%)
Updated May 16, 2024 12:53 PM ET
2-Buy of 5 2
F Value C Growth D Momentum F VGM
Brokerage Reports
Biorestorative Therapies, Inc. [BRTX]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Signs Commercial Deal with Medical Aesthetics Technology Company Cartessa
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Ongoing BRTX-100 Trial Can Use Sham Injection Control Rather Than Saline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Galen To Help Speed Phase 2 Enrollment, Which Should Finish By YE24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Recent Encouraging Blinded Preliminary Phase 2 BRTX-100 Data in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging, Albeit Blinded, Preliminary Phase 2 BRTX-100 Data in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Signs Potentially Lucrative Supply Agreement With Evolutionary Biologics
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Northwell Health Activated As a Phase 2 Trial Site for BRTX-100 in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
2Q23: Low Valuation Undeserved, BRTX-100 Safe, 10-Q Filed, Cash Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Stock Weakness On Highly Misleading Chatroom Information, CEO Buys Shares
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
DSMB Unanimously Recommends Continuing Phase 2 cLDD Trial Without Changes
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Doses Final Safety Run-In Patient In Phase 2 cLDD Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Licensed by NYS DoH as a Tissue Bank for Mesenchymal Stem Cell Processing
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Physician Interview Highlights Favorable View of BRTX-100 in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J